GlaxoSmithKline (GSK) has inked an exclusive over-the-counter license agreement covering the United States and Canada for a nanoemulsion treatment for cold sores developed by Ann Arbor, MI-based NanoBio Corporation. James R. Baker, Jr., MD, director of the Michigan Nanotechnology Institute for Medicine and Biological Sciences at the University of Michigan Medical School, developed nanoemulsions in the 1990s at U-M and founded NanoBio. The nanoemulsion technology is patented by U-M and licensed to NanoBio, where Baker serves as CEO. “For the university, this agreement demonstrates the value of our technology and fulfills our goal of getting the benefits of our research deployed broadly to the general public,” says Ken Nisbet, executive director of the U-M’s OTT.<\/p>\n
Nanoemulsions are superfine mixtures of soybean oil and water, stabilized by surfactants and blended at very high speeds so that the resulting droplets are less than 400 nanometers in diameter. Nanoemulsion droplets fuse with a microbe’s outer membrane, disrupt the membrane, and kill the organism. Under the agreement, New Jersey-based GSK will pay NanoBio an up-front fee of $14.5 million for licensing rights to the nanoemulsion product, called NB-001. NanoBio is eligible to receive additional milestone payments of up to $40 million plus high single-digit royalties on future sales. Baker believes that the GSK-NanoBio partnership will “enable the development and commercialization of NB-001 to its fullest potential and validate the promise of our proprietary platform technology and its potential use in a wide range of dermatological and anti-infective applications.”<\/p>\n
In a separate development, GSK is partnering with scientists at the Emory Institute for Drug Discovery (EIDD) in Atlanta and with Alnylam Pharmaceuticals on research to develop new drugs for neglected tropical diseases in underdeveloped countries. Emory signed a Memorandum of Understanding with GSK as the first university to join the company’s new “intellectual property pool,” consisting of hundreds of patents and patent applications, scientific reports, and analyses. Under the MoU, Emory will have access to GSK scientists who can provide information about the history and current development of selected compounds targeting 16 neglected diseases identified by the U.S. Food and Drug Administration: tuberculosis, malaria, blinding trachoma, buruli ulcer, cholera, dengue\/dengue haemorrhagic fever, racunculiasis, fascioliasis, human African trypanosomiasis, leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis, schistosomiasis, soil transmitted helminthiasis, and yaws.<\/p>\n
The patents in the IP pool are not generally filed in the least developed countries, and the new initiative is designed to encourage R&D of new medicines for these countries, as defined by the United Nations. The MoU states that, once the EIDD identifies technologies or selected compounds to pursue, Emory and GSK will develop a license agreement and additional collaborative research aimed at advancing the development of new medicines. The independent group BIO Ventures for Global Health will administer GSK’s IP pool. GSK also will collaborate with Alnylam Pharmaceuticals and the South African company iThemba Pharmaceuticals, using the IP pool, to encourage R&D into new medicines to treat tuberculosis. iThemba, founded in 2003 by Dennis Liotta, PhD, professor of chemistry at Emory, and research partners in the United Kingdom, the United States, and South Africa, is developing new and affordable medicines for infectious diseases of the poor.<\/p>\n
Sources: zikkir Technology News<\/a> and Health News Digest<\/a><\/p>\n GlaxoSmithKline (GSK) has inked an exclusive over-the-counter license agreement covering the United States and Canada for a nanoemulsion treatment for cold sores developed by Ann Arbor, MI-based NanoBio Corporation. James R. Baker, Jr., MD, director of the Michigan Nanotechnology Institute for Medicine and Biological Sciences at the University of Michigan Medical School, developed nanoemulsions in […]<\/p>\n","protected":false},"author":67,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-239385","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/239385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/67"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=239385"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/239385\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=239385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=239385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=239385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/p>\n","protected":false},"excerpt":{"rendered":"